GSK adds to COPD pipeline as Exscientia deal bears fruit

GSK | April 05, 2019

GSK adds to COPD pipeline as Exscientia deal bears fruit
AI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D tie-up signed in 2017. Under the deal Exscientia will develop small molecule drugs for up to 10 disease targets nominated by GSK, and is worth up to £33 million if all these milestones are met. The Oxford biotech gave no details about how much it got paid for submitting this first active lead molecule for development by GSK, but said it is a highly potent in vivo molecule targeting a novel pathway for chronic obstructive pulmonary disease (COPD). Developing new respiratory disease drugs is a priority for GSK, which is under pressure after generics of its ageing blockbuster COPD and asthma inhaler Advair have finally been launched in the US market. Mylan in February launched its Advair generic at a 70% discount to Advair, and although GSK has a new generation of respiratory drugs on the market, none of them have gained as much traction as Advair.

Spotlight

Jantec Pharma Exclusive Products with world class Packing.Packing is an integral part of any Products. Jantec Pharma has taken care of its exclusive products with its eminent packings.

Related News

PHARMA TECH

Sebela Pharmaceuticals Announces U.S. Launch of SUTAB® Tablets, An Alternative to Liquid Colonoscopy Preparation

Sebela Pharmaceuticals | January 06, 2021

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alternative to liquid colonoscopy preparations, which traditionally require consuming large volumes of poor-tasting solution and can often be a barrier to patients' willingness to undergo colonoscopy screening for colorectal cancer. 1 The American Cancer Society and the U.S. Preventive Services Task Force recommend adults undergo screening for colorectal cancer beginning at age 45.2 Colonoscopy is the gold standard detection method for colorectal cancer, a leading cause of cancer-related deaths that can be more effectively treated if caught early through screening.3 Within the last decade, the rate of colonoscopy procedures has increased significantly with approximately 18 million people now screened annually for colorectal cancer. "Alternative colonoscopy preparations, like SUTAB, can play an important role in encouraging more patients to get screened for colorectal cancer," said Alan Cooke, President and CEO of Sebela Pharmaceuticals. "With the introduction of SUTAB tablets, we hope to take yet another important step toward removing some of the burden often associated with the preparation process – allowing more patients to feel confident in their choice to undergo a colonoscopy." The FDA approved SUTAB on November 10, 2020. The approval was based on positive Phase 3 clinical trials, which evaluated the safety and efficacy of SUTAB compared to FDA-approved preparations in 941 patients, including a traditional polyethylene glycol and ascorbate preparation (PEG-EA) for bowel cleansing prior to a colonoscopy.4

Read More

CVS head of specialty pharmacy sees future of healthcare at home after Covid-19

Medcity news | May 26, 2020

Mail-order prescriptions are nothing new, but pharmacists have turned to a number of other tools to help patients access their prescriptions during the Covid-19 pandemic. The head of CVS Health’s specialty pharmacy strategy, Prem Shah, said he expects to see more patients continue receive healthcare at home after the pandemic ends. Though CVS Health had been building up its arsenal of digital tools before the Covid-19 pandemic, stay-at-home orders forced the pharmacy giant to lean more on them. The company has seen a surge in the use of its support services since the beginning of March.

Read More

FiercePharmaPolitics—Gilead CEO sees COVID-19 changing the drug pricing conversation

Fiercepharma | May 04, 2020

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewhere that could affect drug pricing and how drugmakers operate. With less than six months to go until the U.S. elections, the pharma industry finds itself in a different position than expected at the start of the year. While many predicted a tense year as candidates went on the attack, the pandemic has taken the spotlight. And instead of being an easy target, pharma companies have found a chance to shine. On Gilead Sciences' first-quarter conference call, Mizuho analyst Salim Syed pointed out that rhetoric around pharmaceuticals and drug pricing has been “pretty negative” in recent years. So, the analyst wondered aloud whether that has changed as Gilead and other drugmakers charge forward with potential COVID-19 therapies.

Read More

Spotlight

Jantec Pharma Exclusive Products with world class Packing.Packing is an integral part of any Products. Jantec Pharma has taken care of its exclusive products with its eminent packings.